The stock of InVitae Corp (NYSE:NVTA) is a huge mover today! About 213,669 shares traded hands. InVitae Corp (NYSE:NVTA) has declined 34.74% since April 21, 2016 and is downtrending. It has underperformed by 40.07% the S&P500.
The move comes after 9 months positive chart setup for the $296.33 million company. It was reported on Nov, 23 by Barchart.com. We have $7.60 PT which if reached, will make NYSE:NVTA worth $11.85M more.
Analysts await InVitae Corp (NYSE:NVTA) to report earnings on February, 14. They expect $-0.66 earnings per share, up 13.16% or $0.10 from last year’s $-0.76 per share. After $-0.77 actual earnings per share reported by InVitae Corp for the previous quarter, Wall Street now forecasts -14.29% EPS growth.
InVitae Corp (NYSE:NVTA) Ratings Coverage
Out of 3 analysts covering Invitae (NYSE:NVTA), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. Invitae has been the topic of 4 analyst reports since August 14, 2015 according to StockzIntelligence Inc. The rating was maintained by JP Morgan with “Overweight” on Tuesday, August 9. William Blair initiated the stock with “Mkt Perform” rating in Friday, August 14 report. Leerink Swann downgraded the shares of NVTA in a report on Thursday, January 28 to “Mkt Perform” rating. The company was reinitiated on Thursday, November 10 by Leerink Swann.
According to Zacks Investment Research, “Invitae Corporation is engaged in genetic diagnostics for hereditary disorders which include breast, colon and pancreatic cancer. It operates primarily in the United States, Israel and internationally. Invitae Corporation is headquartered in San Francisco, California.”
More important recent InVitae Corp (NYSE:NVTA) news were published by: Businesswire.com which released: “Invitae Announces Pricing of Public Offering of Common Stock” on November 17, 2016, also Reuters.com published article titled: “BRIEF-Invitae Corp entered into a provider agreement for laboratory servic…”, Streetinsider.com published: “Form 4 Invitae Corp For: Nov 18 Filed by: Crouse Geoffrey” on November 22, 2016. More interesting news about InVitae Corp (NYSE:NVTA) was released by: Businesswire.com and their article: “Invitae Announces Proposed Public Offering of Common Stock” with publication date: November 15, 2016.
NVTA Company Profile
Invitae Corporation (Invitae), incorporated on January 13, 2010, utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. The Company’s laboratory is located in San Francisco, California. The Company’s product is an assay of over 600 genes that can be used for multiple indications. The test includes multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders and other hereditary conditions.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.